Association of genetic variants in CYP2C19 and adverse clinical outcomes after treatment with clopidogrel: An updated meta-analysis
- 31 December 2011
- journal article
- other
- Published by Elsevier BV in Thrombosis Research
- Vol. 128 (6), 593-594
- https://doi.org/10.1016/j.thromres.2011.07.003
Abstract
No abstract availableThis publication has 18 references indexed in Scilit:
- Effects ofCYP2C19Genotype on Outcomes of Clopidogrel TreatmentNew England Journal of Medicine, 2010
- Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trialThe Lancet, 2010
- Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular eventsAmerican Heart Journal, 2010
- Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel TherapyJAMA, 2009
- Relation of Cytochrome P450 2C19 Loss-of-Function Polymorphism to Occurrence of Drug-Eluting Coronary Stent ThrombosisThe American Journal of Cardiology, 2009
- Cytochrome P-450 Polymorphisms and Response to ClopidogrelNew England Journal of Medicine, 2009
- Genetic Determinants of Response to Clopidogrel and Cardiovascular EventsNew England Journal of Medicine, 2009
- Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort studyThe Lancet, 2009
- Cytochrome P450 2C19 681G>A Polymorphism and High On-Clopidogrel Platelet Reactivity Associated With Adverse 1-Year Clinical Outcome of Elective Percutaneous Coronary Intervention With Drug-Eluting or Bare-Metal StentsJournal of the American College of Cardiology, 2008
- Coexisting Polymorphisms of P2Y12 and CYP2C19 Genes as a Risk Factor for Persistent Platelet Activation With ClopidogrelCirculation Journal, 2008